Takeda Pharmaceutical

Latest Headlines

Latest Headlines

Contrave trial tussle brews between Takeda, Orexigen with Cleveland Clinic on the scene

A tussle over the termination of a trial to assess the cardiovascular safety of obesity drug Contrave is in swing, with Orexigen Therapeutics and Takeda Pharmaceutical entering a dispute process, according to Reuters, with earlier data breaches the subject of a separate issue.

Takeda, Orexigen end CV study for obesity drug Contrave

Takeda Development Center Americas, a unit of Japan's Takeda Pharmaceutical, and Orexigen Therapeutics have ended a cardiovascular outcomes trial that compared the obesity drug Contrave to a placebo in addition to diet and exercise counselling, in 8,909 overweight and obese patients with certain CV risk factors, the companies said.

Takeda joins with Japan's National Cancer Center on genomic screening

Takeda Pharmaceutical and Japan's National Cancer Center have entered into a plan to find and develop anticancer agents and a way to get them to Japanese patients quickly. The plan, in part, is to build on their collaboration on a genomic screening project led by the NCC.

Sumitomo Dainippon, Takeda call it quits on Latuda agreement in Europe

Sumitomo Dainippon Pharma and Takeda Pharmaceutical have canceled a four-year-old license and development agreement aimed at commercialization of lurasidone hydrochloride (Latuda) products following disappointing Phase III trials to treat schizophrenia announced last month.

Takeda financial hit from Actos settlement won't dim dividend

Takeda Pharmaceutical is about to make history that it would prefer not to make. When it produces its quarterly report for the fiscal year that ended March 31, it is expected to post its first net loss since it first listed on the Tokyo Stock Exchange in 1949.

BioXcel adds Takeda to its roster of A-list clients

BioXcel has added another big name to its list of clients. Takeda is the latest company to sign up to work with BioXcel, a database-driven drug discovery shop that already boasts relationships with Alexion, Sanofi, Teva and Vertex.

AZ's Onglyza has most to lose at FDA safety confab, analysts say

FDA experts will grill a couple of diabetes meds next Tuesday, and the outcome of that debate could put a damper on sales. The drugs: AstraZeneca's Onglyza and Takeda's Nesina, both DPP-4 blood sugar-fighters. The questions: Do they really increase the risk of heart failure? And if so, what's to be done about it?

Takeda looks to settle thousands of Actos U.S. lawsuits for $2B

Takeda Pharmaceutical has offered $2.2 billion to settle all U.S. claims linked to its diabetes drug Actos as it battles thousands of cases and stretches legal resources even with some verdicts favorable, a report said April 1.

Infinity pulls trigger on Takeda oncology candidate option

Infinity Pharmaceuticals exercised an option this week to purchase worldwide royalty obligations ranging from 7% to 11% on sales of duvelisib (IPI-145) in oncology indications from Takeda Pharmaceutical for $52.5 million.

Busy Takeda transfers HPV vaccine candidate to research institute for development

Takeda Pharmaceutical said it has done its job and is bowing out of further development of a human papillomavirus vaccine.